{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:50Z","timestamp":1788391190171,"version":"build-2803163510"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"685-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards"],"prefix":"10.1016","volume":"40","author":[{"given":"Yu","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.hoc.2026.05.019_bib2","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.019_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.019_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.019_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.hoc.2026.05.019_bib6","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.019_bib7","doi-asserted-by":"crossref","first-page":"e000094","DOI":"10.1136\/esmoopen-2016-000094","article-title":"Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls","volume":"1","author":"Horak","year":"2016","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.019_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/2159-8290.CD-19-1265","article-title":"Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.019_bib9","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-23-0090","article-title":"Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications","volume":"29","author":"Gouda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib10","first-page":"955","article-title":"Personalized immunotherapy in cancer precision medicine","volume":"18","author":"Kiyotani","year":"2021","journal-title":"Cancer Biol Med"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.019_bib11","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.019_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.019_bib13","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non\u2013small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.019_bib14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.019_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.019_bib16","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.019_bib17","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.019_bib19","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2026.05.019_bib20","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.019_bib21","first-page":"1","article-title":"Current Insights on the treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer: focus on brigatinib","volume":"14","author":"Rijavec","year":"2022","journal-title":"Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.019_bib24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.019_bib25","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cncr.29364","article-title":"Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer","volume":"121","author":"Kinugasa","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib26","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.019_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2026.05.019_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","article-title":"Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer","volume":"11","author":"Baselga","year":"2006","journal-title":"Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.019_bib29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.019_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.019_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.019_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.019_bib33","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.019_bib34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.019_bib35","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10308","key":"10.1016\/j.hoc.2026.05.019_bib36","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.019_bib39","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2026.05.019_bib40","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.019_bib42","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","article-title":"Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","volume":"12","author":"Tsimberidou","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.019_bib44","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"33","key":"10.1016\/j.hoc.2026.05.019_bib45","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib46","first-page":"6","article-title":"Benchmark of actionability","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.019_bib47","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.019_bib48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/1535-7163.MCT-15-0795","article-title":"Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience","volume":"15","author":"Schwaederle","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.019_bib51","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/1878-0261.13202","article-title":"Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience","volume":"16","author":"Louie","year":"2022","journal-title":"Mol Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2026.05.019_bib52","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.019_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.019_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib55","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.019_bib57","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.hoc.2026.05.019_bib58","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.019_bib59","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.019_bib60","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.019_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy","volume":"86","author":"Barker","year":"2009","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.019_bib63","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/oncolo\/oyac069","article-title":"Developing a virtual equity hub: adapting the tumor board model for equity in cancer care","volume":"27","author":"Irwin","year":"2022","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jamiaopen\/ooz045","article-title":"A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients","volume":"2","author":"Pishvaian","year":"2019","journal-title":"JAMIA Open"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.019_bib65","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ijgc-2022-003425","article-title":"A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group","volume":"32","author":"Michele","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/2159-8290.CD-21-1064","article-title":"Genomic landscape and clinical utility in Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program","volume":"12","author":"Park","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.019_bib67","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/ijc.31091","article-title":"Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study","volume":"142","author":"Heong","year":"2018","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.019_bib68","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.019_bib69","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/2159-8290.CD-22-0024","article-title":"Think globally, act locally: globalizing precision oncology","volume":"12","author":"Moyers","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.05.019_bib70","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fonc.2018.00346","article-title":"Global Inequities in precision medicine and molecular cancer research","volume":"8","author":"Drake","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.019_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/annonc\/mdw018","article-title":"Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol","volume":"27","author":"Meric-Bernstam","year":"2016","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.019_bib72","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1158\/1078-0432.CCR-16-0015","article-title":"Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings","volume":"22","author":"Seifert","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA","volume":"2","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.019_bib74","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JOP.19.00201","article-title":"When should tumor genomic profiling prompt consideration of germline testing?","volume":"15","author":"DeLeonardis","year":"2019","journal-title":"Journal of Oncology Practice"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.019_bib75","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine-moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.019_bib77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.019_bib78","first-page":"252","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","volume":"3","author":"Fujiwara","year":"2020","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.019_bib79","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"17_suppl","key":"10.1016\/j.hoc.2026.05.019_bib80","doi-asserted-by":"crossref","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.019_bib81","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.019_bib82","article-title":"Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study","volume":"2018","author":"Mangat","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.019_bib83","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.20.02923","article-title":"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) Study","volume":"39","author":"Alva","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.019_bib84","doi-asserted-by":"crossref","first-page":"e2200609","DOI":"10.1200\/PO.22.00609","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: results from the TAPUR study","volume":"7","author":"Ahn","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-021-00159-2","article-title":"Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study","volume":"5","author":"Tsimberidou","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.019_bib86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","article-title":"From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm","volume":"7","author":"Adashek","year":"2021","journal-title":"Trends Cancer"},{"issue":"9453","key":"10.1016\/j.hoc.2026.05.019_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.019_bib88","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.019_bib89","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.019_bib90","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-MUTATED MELAnoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2026.05.019_bib91","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:44Z","timestamp":1788390104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000614"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.019","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}